

U.S. Vaccines: Table 1
(For Combination Vaccines, See Table 2)

| Vaccine | Trade Name | Abbreviation | Manufacturer | Type / Route | Approved | Comments |
|--|----------------------------|---------------|-----------------------|--|----------|--|
| Adenovirus | Adenovirus Type 4 & Type 7 | | Barr Labs Inc. | Live Viral / Oral (tablets) | 2011 | Approved for military populations 17 through 50 years. |
| Anthrax | BioThrax® | AVA | Emergent BioSolutions | Inactivated Bacterial / IM | 1970 | Age range 18 through 65 years |
| Cholera | Vaxchora® | | PaxVax | Live Bacterial / Oral | 2016 | Age range 18 through 64 years. |
| DTaP | Daptacel® | DTaP | sanofi | Inactivated Toxoids and Bacterial / IM | 2002 | Age range 6 weeks through 6 years. |
| | Infanrix® | DTaP | GlaxoSmithKline | Inactivated Toxoids and Bacterial / IM | 1997 | Age range 6 weeks through 6 years. |
| DT | Generic | DT | sanofi | Inactivated Bacterial Toxoids / IM | 1978 | Age range 6 months through 6 years. |
| <i>Haemophilus influenzae</i> type b (Hib) | ActHIB® | Hib (PRP-T) | sanofi | Inactivated Bacterial / IM | 1993 | 3-dose primary series |
| | Hiberix® | Hib (PRP-T) | GlaxoSmithKline | Inactivated Bacterial / IM | 2009 | 3-dose primary series |
| | PedvaxHIB® | Hib (PRP-OMP) | Merck | Inactivated Bacterial / IM | 1989 | 2-dose primary series |
| Hepatitis A | Havrix® | HepA | GlaxoSmithKline | Inactivated Viral / IM | 1995 | Pediatric & adult formulations. Minimum age = 1 year |
| | Vaqta® | HepA | Merck | Inactivated Viral / IM | 1996 | Pediatric & adult formulations. Minimum age = 1 year |
| Hepatitis B | Engerix-B® | HepB | GlaxoSmithKline | Recombinant Viral / IM | 1989 | Pediatric & adult formulations. Minimum age = birth |
| | Recombivax HB® | HepB | Merck | Recombinant Viral / IM | 1986 | Pediatric & adult formulations. Minimum age = birth |
| | Heplisav-B® | HepB | Dynavax Technologies | Recombinant Viral / IM | 2017 | Adjuvanted Minimum age = 18 years |
| Herpes Zoster (Shingles) | Zostavax® | ZVL | Merck | Live Attenuated Viral / SC | 2006 | One dose: Minimum age = 50 years. (ACIP recommends ≥60 years.) |
| | Shingrix® | RZV | GlaxoSmithKline | Recombinant Viral / IM | 2017 | Two doses: Minimum age = 50 years. |
| Human Papillomavirus (HPV) | Gardasil® 9 | 9vHPV | Merck | Inactivated Viral / IM | 2014 | Approved for males and females 9 through 26 years. |

| Vaccine | Trade Name | Abbreviation | Manufacturer | Type / Route | Approved | Comments |
|----------------------------|-------------------------|-----------------|-----------------|---|-------------------------------|--|
| Influenza | Afluria® | IIV3 IIV4 | Seqirus | Inactivated Viral / IM | 2007 2016 | Minimum age = 5 years |
| | Fluad® | IIV3 | Seqirus | Inactivated Viral / IM | 2015 | Adjuvanted Minimum age = 65 years |
| | Fluarix® | IIV4 | GlaxoSmithKline | Inactivated Viral / IM | 2012 | Minimum age = 6 months |
| | Flublok® | RIV3 RIV4 | sanofi | Recombinant Viral / IM | 2013 | Egg Free Minimum age = 18 years |
| | Flucelvax® | ccIIV4 | Seqirus | Cell-culture Viral / IM | 2016 | Minimum age = 4 years |
| | FluLaval® | IIV4 | GlaxoSmithKline | Inactivated Viral / IM | 2013 | Minimum age = 6 months |
| | FluMist® | LAIV4 | Medimmune | Live Attenuated Viral / Intranasal (spray) | 2003 | Age range 2 through 49 years |
| | Fluvirin® | IIV3 | Seqirus | Inactivated Viral / IM | 1988 | Minimum age = 4 years |
| | Fluzone® | IIV3 IIV4 | sanofi | Inactivated Viral / IM | 1980 2013 | Minimum age = 6 months |
| | Fluzone® High-Dose | IIV3 | sanofi | Inactivated Viral / IM | 2009 | Minimum age = 65 years |
| | Fluzone® Intradermal | IIV4 | sanofi | Inactivated Viral / Intradermal | 2011 | Age range 18 through 64 years |
| Japanese encephalitis | Ixiaro® | JE | Valneva | Inactivated Viral / IM | 2009 | Minimum age = 2 months |
| Measles, Mumps, Rubella | M-M-R® II | MMR | Merck | Live Attenuated Viral / SC | 1978 (First MMR – 1971) | Minimum age = 12 months |
| Meningococcal | Menactra® | MCV4 MenACWY | sanofi | Inactivated Bacterial / IM | 2005 | Age range 9 months through 55 years |
| | Menveo® | MCV4 MenACWY | GlaxoSmithKline | Inactivated Bacterial / IM | 2010 | Age range 2 months through 55 years |
| | Trumenba® | MenB | Pfizer | Recombinant Bacterial / IM | 2014 | Age range 10 through 25 years |
| | Bexsero® | MenB | GlaxoSmithKline | Recombinant Bacterial / IM | 2015 | Age range 10 through 25 years |

| Vaccine | Trade Name | Abbreviation | Manufacturer | Type / Route | Approved | Comments |
|--|----------------|--------------|-------------------------------|---|--------------------|--|
| Pneumococcal | Pneumovax® 23 | PPSV23 | Merck | Inactivated Bacterial / SC or IM | 1983 | Minimum age = 2 years |
| | Prevnar 13® | PCV13 | Pfizer | Inactivated Bacterial / IM | 2010 (PCV7 – 2000) | Minimum age = 6 weeks |
| Polio | Ipol® | IPV | sanofi | Inactivated Viral / SC or IM | 1990 (IPV-1955) | Minimum age = 6 weeks |
| Rabies | Imovax® Rabies | | sanofi | Inactivated Viral / IM | 1980 | All ages |
| | RabAvert® | | GlaxoSmithKline | Inactivated Viral / IM | 1997 | All ages |
| Rotavirus | RotaTeq® | RV5 | Merck | Live Viral / Oral (liquid) | 2006 | 3-dose series 1 st dose 6 through 14 weeks 3 rd dose max age 8 months 0 days |
| | Rotarix® | RV1 | GlaxoSmithKline | Live Viral / Oral (liquid) | 2008 | 2-dose series 1 st dose 6 through 14 weeks 2 nd dose max age 8 months 0 days |
| Tetanus, (reduced) Diphtheria | Tenivac® | Td | sanofi | Inactivated Bacterial Toxoids / IM | 2003 | Minimum age = 7 years |
| | (Generic) | Td | Massachusetts Biological Labs | Inactivated Bacterial Toxoids / IM | 1967 | Minimum age = 7 years |
| Tetanus, (reduced) Diphtheria, (reduced) Pertussis | Boostrix® | Tdap | GlaxoSmithKline | Inactivated Bacterial / IM | 2005 | Minimum age = 10 years |
| | Adacel® | Tdap | sanofi | Inactivated Bacterial / IM | 2005 | Age range 10 through 64 years |
| Typhoid | Typhim Vi® | | sanofi | Inactivated Bacterial / IM | 1994 | Minimum age = 2 years |
| | Vivotif® | | PaxVax | Live Attenuated Bacterial / Oral (4 capsules) | 1989 | Minimum age = 6 years |
| Varicella | Varivax® | VAR | Merck | Live Attenuated Viral / SC | 1995 | Minimum age = 12 months |
| Vaccinia (Smallpox) | ACAM2000® | | sanofi | Live Attenuated Viral / Percutaneous | 2007 | All ages |
| Yellow Fever | YF-Vax® | YF | sanofi | Live Attenuated Viral / SC | 1978 | Minimum age = 9 months |

U.S. Vaccines: Table 2 (Combination Vaccines)

| Vaccine | Trade Name | Abbreviation | Manufacturer | Type / Route | Approved | Comments |
|---|------------|---------------|-----------------|------------------------------------|----------|--|
| DTaP, Polio | Kinrix® | DTaP-IPV | GlaxoSmithKline | Inactivated Bacterial & Viral / IM | 2008 | Approved for 5 th (DTaP) and 4 th (IPV) booster at 4-6 years |
| | QuadraceI™ | DTaP-IPV | sanofi | Inactivated Bacterial & Viral / IM | 2015 | Approved for 5 th (DTaP) and 4 th (IPV) booster at 4-6 years |
| DTaP, hepatitis B, Polio | Pediarix® | DTaP-HepB-IPV | GlaxoSmithKline | Inactivated Bacterial & Viral / IM | 2002 | Age range 6 weeks through 6 years |
| DTaP, Polio, <i>Haemophilus influenzae</i> type b | Pentacel® | DTaP-IPV/Hib | sanofi | Inactivated Bacterial & Viral / IM | 2008 | Age range 6 weeks through 4 years |
| Hepatitis A, Hepatitis B | Twinrix® | HepA-HepB | GlaxoSmithKline | Inactivated/Recombinant Viral / IM | 2001 | Pediatric HepA + Adult HepB Minimum age = 18 years |
| Measles, Mumps, Rubella, Varicella | ProQuad® | MMRV | Merck | Live Attenuated Viral / SC | 2005 | Age range 1 through 12 years |

Abbreviations

The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the *Morbidity and Mortality Weekly Report (MMWR)*, the editor of *Epidemiology and Prevention of Vaccine-Preventable Diseases* (the *Pink Book*), ACIP members, and liaison organizations to the ACIP.

These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the *MMWR*, the *Pink Book*, and the American Academy of Pediatrics *Red Book*, and in the U.S. immunization schedules for children, adolescents, and adults.

In descriptions of combination vaccines, dash (-) indicates: products in which the active components are supplied in their final (combined) form by the manufacturer; slash (/) indicates: products in which active components must be mixed by the user.